Nephrology

Unicycive Announces Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, November 14, 2023

LOS ALTOS, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the third quarter ended September 30, 2023, and provided a business update.

Key Points: 
  • LOS ALTOS, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the third quarter ended September 30, 2023, and provided a business update.
  • We also remain very active within the the medical community with a booth at Kidney Week and positive results published on the phosphate binding capacity for OLC,” concluded Dr. Gupta.
  • Unicycive believes that results from this pivotal trial will enhance the OLC data package from preclinical studies and our previously disclosed bioequivalence study.
  • Dr. Kenkare-Mitra brings Unicycive expertise spanning research, preclinical and clinical development, translational medicine, manufacturing, and regulatory.

ProKidney Announces Positive Interim Data from RMCL-002 Phase 2 Clinical Trial of Renal Autologous Cell Therapy (REACT®) for Diabetic CKD and Provides Corporate Updates

Retrieved on: 
Monday, November 13, 2023

Positive interim Phase 2 data demonstrate the potential of REACT® to preserve kidney function in moderate and high-risk diabetic CKD patients.

Key Points: 
  • Positive interim Phase 2 data demonstrate the potential of REACT® to preserve kidney function in moderate and high-risk diabetic CKD patients.
  • Updated interim REACT RMCL-002 study data support continued investigation of REACT’s potential to benefit patients with moderate and high-risk diabetic CKD.
  • The ongoing Phase 2 clinical study assessed adverse events and changes in kidney function as measured by estimated glomerular filtration rate (eGFR), as primary study endpoints.
  • Further, you may listen to the presentation by dialing 1-877-407-0784 (US) or 1-201-689-8560 (International) and entering the Conference ID: 13742672.

Annexon Reports Significant Progress with its Priority Programs and Third Quarter 2023 Financial Results

Retrieved on: 
Monday, November 13, 2023

EMA orphan drug designation requires that a novel rare disease therapeutic demonstrates the potential for significant benefit over available therapies.

Key Points: 
  • EMA orphan drug designation requires that a novel rare disease therapeutic demonstrates the potential for significant benefit over available therapies.
  • Importantly, Annexon also announced that it has achieved target enrollment of 225 patients in the randomized, double-blind, placebo-controlled Phase 3 trial of ANX005 in patients with GBS.
  • Research and development (R&D) expenses: R&D expenses were $27.9 million for the quarter ended September 30, 2023, reflecting the advancement of the company’s priority programs, including GBS, GA and ANX1502, compared to $27.9 million for the quarter ended September 30, 2022.
  • General and administrative (G&A) expenses: G&A expenses were $6.9 million for the quarter ended September 30, 2023, compared to $8.2 million for the quarter ended September 30, 2022.

ULTOMIRIS: A Complement Inhibitor for Treating Adult Patients with PNH - Drug Insights and Market Forecasts to 2032 with Focus on 7MM - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 14, 2023

This report provides comprehensive insights about ULTOMIRIS for paroxysmal nocturnal hemoglobinuria (PNH) in the seven major markets.

Key Points: 
  • This report provides comprehensive insights about ULTOMIRIS for paroxysmal nocturnal hemoglobinuria (PNH) in the seven major markets.
  • The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities.
  • Further, it also consists of future market assessments inclusive of the ULTOMIRIS market forecast analysis for PNH in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in PNH.
  • ULTOMIRIS is a complement inhibitor for treating adult patients with PNH.

CORE Kidney Unveils 2024 Rose Parade® Float - A Tribute to the Kidney Donors Who Gifted a Part of Themselves to Save a Life

Retrieved on: 
Tuesday, November 28, 2023

CORE Kidney’s mission is to bring light to how widespread kidney disease is, with the goal of inspiring more people to take preventive measures.

Key Points: 
  • CORE Kidney’s mission is to bring light to how widespread kidney disease is, with the goal of inspiring more people to take preventive measures.
  • CORE Kidney is sending a direct message to the donors across the world to honor their courageous journey.
  • “To all the living kidney donors around the world, CORE is humbled by your life saving donation.
  • Green ribbon: a symbol of kidney health — a call back to the Green Ribbon Campaign started in 2016 by CORE Kidney that raised awareness for kidney health.

Children’s Hospital Los Angeles Recognized as National Surgical Quality Partner by American College of Surgeons

Retrieved on: 
Tuesday, November 21, 2023

Children’s Hospital Los Angeles (CHLA) has been recognized as a National Surgical Quality Partner (SQP) by the American College of Surgeons (ACS) for its long-standing dedication to the highest standards in surgical patient care.

Key Points: 
  • Children’s Hospital Los Angeles (CHLA) has been recognized as a National Surgical Quality Partner (SQP) by the American College of Surgeons (ACS) for its long-standing dedication to the highest standards in surgical patient care.
  • View the full release here: https://www.businesswire.com/news/home/20231121829446/en/
    Children’s Hospital Los Angeles leadership and team members gather in front of the newly installed American College of Surgeons Surgical Quality Partner plaque.
  • The SQP designation lets patients know that Children’s Hospital Los Angeles is dedicated to relentless self-improvement and has been verified through a detailed and rigorous review from ACS.
  • “We are immensely proud to be named an ACS Surgical Quality Partner,” said James Stein, MD, MSc, FACS, FAAP, Senior Vice President and Chief Medical Officer at Children’s Hospital Los Angeles.

Kidneylink Announces Program Growth in Value-Based Kidney Care

Retrieved on: 
Wednesday, December 13, 2023

PLANO, Texas, Dec. 13, 2023 /PRNewswire/ -- Kidneylink – a national, value-based kidney care company founded by U.S. Renal Care, is pleased to announce significant growth and success on behalf of its patients and providers – expanding its network to more than 600 nephrologists across 20 U.S. based markets and caring for more than 16,000 people living with kidney disease, both Chronic Kidney Disease (CKD) and End Stage Kidney Disease (ESKD). Since its inception in 2021, Kidneylink has improved clinical outcomes for patients resulting in double-digit percentage reductions in hospitalizations and medical costs.

Key Points: 
  • PLANO, Texas, Dec. 13, 2023 /PRNewswire/ -- Kidneylink – a national, value-based kidney care company founded by U.S. Renal Care , is pleased to announce significant growth and success on behalf of its patients and providers – expanding its network to more than 600 nephrologists across 20 U.S. based markets and caring for more than 16,000 people living with kidney disease, both Chronic Kidney Disease (CKD) and End Stage Kidney Disease (ESKD).
  • Kidneylink is also not limited to U.S. Renal Care dialysis centers—more than 50% of Kidneylink ESKD patients are treated outside of USRC's facilities.
  • Many value-based kidney organizations rely on virtual care management teams that work around the nephrologist.
  • The future of kidney care is value-based care.

Boston Medical Center to Offer First FDA-Approved Gene Therapy Treatment Program for Sickle Cell Disease

Retrieved on: 
Friday, December 8, 2023

BOSTON, Dec. 8, 2023 /PRNewswire/ -- Boston Medical Center (BMC), a national leader in the treatment of sickle cell disease for more than 50 years, announced today that it will offer the first-ever gene therapy treatment program for sickle cell disease that uses a type of novel genome editing technology. The new therapy leverages the latest advances in medical science to alleviate the severe painful vaso-occlusive crises (VOCs) associated with sickle cell disease, in a long-awaited step toward equity for a disproportionally impacted Black patient population.

Key Points: 
  • BOSTON, Dec. 8, 2023 /PRNewswire/ -- Boston Medical Center (BMC), a national leader in the treatment of sickle cell disease for more than 50 years, announced today that it will offer the first-ever gene therapy treatment program for sickle cell disease that uses a type of novel genome editing technology.
  • The announcement comes as the FDA today granted approval of this new therapy, jointly developed by Boston-based Vertex Pharmaceuticals and CRISPR Therapeutics of Switzerland, along with approval of another cell-based gene therapy for sickle cell disease.
  • BMC is the only hospital in New England to offer the Vertex Pharmaceuticals and CRISPR Therapeutics therapy to eligible adults with sickle cell disease.
  • "Boston Medical Center has a longstanding commitment to providing advanced clinical care to those with sickle cell disease," said Dr. Jean-Antoine Ribeil, MD, PhD, Clinical Director of the Center of Excellence in Sickle Cell Disease at Boston Medical Center and an internationally renowned hematologist who has dedicated his career to the development of gene therapies for patients with sickle cell disease and beta thalassemia.

Joe DiMaggio Children's Hospital Now Offers More Children's Healthcare Services on Memorial Hospital Miramar Campus

Retrieved on: 
Wednesday, December 6, 2023

MIRAMAR, Fla., Dec. 6, 2023 /PRNewswire-PRWeb/ -- In a significant move aimed at enhancing children's healthcare services in the southwest Broward County, Joe DiMaggio Children's Hospital has expanded its world-class specialty care at Memorial Hospital Miramar. This expansion includes a broader range of services, such as allergy and immunology, cardiology, complex gastroenterology, genetics, otolaryngology (ENT), physical medicine and rehabilitation.

Key Points: 
  • In a significant move aimed at enhancing children's healthcare services in the southwest Broward County, Joe DiMaggio Children's Hospital has expanded its world-class specialty care at Memorial Hospital Miramar.
  • MIRAMAR, Fla., Dec. 6, 2023 /PRNewswire-PRWeb/ -- In a significant move aimed at enhancing children's healthcare services in the southwest Broward County, Joe DiMaggio Children's Hospital has expanded its world-class specialty care at Memorial Hospital Miramar .
  • Joe DiMaggio Children's Hospital is expanding its team of healthcare professionals at the Miramar location to better serve its diverse range of specialties.
  • Moreover, the hospital offers a variety of children's services, such as bone density testing, EEGs, imaging, lab services, and outpatient therapy.

Key Legislation (H.R. 3674) Considered During House Energy and Commerce Committee Markup

Retrieved on: 
Thursday, November 30, 2023

WASHINGTON, Nov. 29, 2023 /PRNewswire-PRWeb/ -- The Providing Relief and Stability for Medicare Patients Act of 2023 (H.R. 3674), legislation to strengthen community and office-based providers, was considered during the Energy and Commerce Health Subcommittee markup held on November 15.

Key Points: 
  • 3674) , legislation to strengthen community and office-based providers, was considered during the Energy and Commerce Health Subcommittee markup held on November 15.
  • 3674 is bipartisan legislation that aims to stop ongoing cuts to office-based specialists for the next two years.
  • I hope that my colleagues agree to work on this legislation and to land on a path forward that supports access to community care.
  • Failing to do so will contribute to already shocking rates of physician shortages and reduces access to care for patients.